BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease

Stock Information for BioNxt Solutions Inc Ordinary Shares

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioNxt Solutions Inc Ordinary Shares

BioNxt Solutions Announces Change of Directors
Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Announces Non-Brokered Private Placement
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
BioNxt Successfully Completes Pilot Study for Contract Development Customer
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
BioNxt Reports on Enteric Coating Drug Delivery Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.